Mar. 26 at 12:24 AM
$IBRX Another company that has faced challenges with the FDA is
$SMMT.
Same type of holdbacks, but
$SMMT has licensed their treatment from a Chinese company, but non the less are posing a serious challenge to Merck’s treatment.
The big pharma appears to have taken a seat at the FDA approval desk.
$SMMT had a good move today, so perhaps the senses at the FDA may be coming back to a fair ground and they may be getting an awaited approval.
Let us hope!!!
